Browsing: breast cancer

Breast cancer is the leading cancer among Southeast Asian women, but early detection through mammograms can significantly improve treatment outcomes. Learn when to get screened, how to prepare for a mammogram, and why knowing your body is key to early detection.

From biomarker-driven therapies to antibody-drug conjugates, new treatments are offering more personalised and effective options for triple negative breast cancer (TNBC), an aggressive subtype of breast cancer. These innovations are helping improve survival rates and transforming how TNBC is managed, but they also come with unique challenges that require careful clinical consideration.

Log In or Register as a healthcare professional to read the full article.

Two ESMO 2024 studies provided reassuring findings on breastfeeding for breast cancer survivors. A study of nearly 5,000 young BRCA mutation carriers and another of 518 women who interrupted treatment to have a baby both found no increased recurrence risk among those who breastfed their babies compared to those who did not breastfeed.

Roche announced today that Tecentriq® SC (atezolizumab) has been approved by the Singapore Health Sciences Authority (HSA) for all indications in which the intravenous (IV) formulation of Tecentriq has been previously approved, including certain types of lung, breast and liver cancer.4 Tecentriq SC is Roche’s fourth subcutaneous cancer therapy,5-7 and the world’s first injectable anti-PD-(L)1 cancer immunotherapy.

Log In or Register as a healthcare professional to read the full article.

Cancer remains a significant public health concern in the Philippines, with the Department of Health (DOH) recording an estimated 153,751 cases in 2020. Among the various types of cancer, breast and cervical cancers stand out as major health challenges affecting women across different demographics and regions.

In conclusion, Herbosa’s advocacy epitomises a concerted effort to ensure accessibility and equity in healthcare access for all Filipinos. The DOH strives to catalyse a paradigm shift towards preventive care and bolster health outcomes nationwide. This is exhibited by advocating for the integration of essential preventive screenings into PhilHealth’s benefit packages and simplifying access for vulnerable populations such as PWDs. Guaranteeing that preventive screenings are readily accessible and financially feasible for all segments of society remains paramount to alleviating disease burden and propelling public health advancements in the Philippines. Herbosa’s initiatives underscore an unwavering commitment to realising universal health coverage and advancing health equity for every Filipino, irrespective of circumstance or background.

Speaker Ferdinand Martin Romualdez’s call for a comprehensive review of PhilHealth’s charter to extend patient benefits resonated strongly with the organisation’s vision. In response, PhilHealth affirmed its alignment with Speaker Martin’s directive, emphasising the urgent need to increase case packages across the board aggressively. Ledesma Jr. reiterated PhilHealth’s commitment to this cause, signalling a proactive approach to driving forward these enhancements in collaboration with key stakeholders.

A team from the NUS Centre for Cancer Research (N2CR) and the Department of Pathology at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), has made a significant discovery in the understanding of breast cancer’s resistance to chemotherapy. The study, led by Research Assistant Professor Leong Sai Mun, spanned over a decade and examined a large cohort of breast cancer patients to understand the dynamics of cancer cell survival post-chemotherapy.